Corvus Pharmaceuticals (CRVS) News Today $3.24 +0.21 (+6.93%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.21 -0.03 (-0.93%) As of 04/15/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of DirectorsApril 9, 2025 | globenewswire.comRaymond James Financial Inc. Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Raymond James Financial Inc. purchased a new stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 108,989 shares of the company's stock, valued at appApril 8, 2025 | marketbeat.comHC Wainwright Has Optimistic View of CRVS FY2025 EarningsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Corvus Pharmaceuticals in a report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.March 29, 2025 | marketbeat.comCorvus Pharmaceuticals: Now At Cruising AltitudeMarch 28, 2025 | seekingalpha.comCorvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising TrialsMarch 28, 2025 | seekingalpha.comHC Wainwright Issues Pessimistic Forecast for CRVS EarningsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright dropped their FY2028 earnings estimates for Corvus Pharmaceuticals in a research report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will post earnings per sMarch 28, 2025 | marketbeat.comCORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly EarningsMarch 27, 2025 | nasdaq.comCorvus Pharmaceuticals price target raised to $15 from $14 at OppenheimerMarch 27, 2025 | markets.businessinsider.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | insidermonkey.comCorvus Pharmaceuticals (NASDAQ:CRVS) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday.March 27, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings ResultsCorvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06).March 26, 2025 | marketbeat.comInsider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m ProfitMarch 26, 2025 | finance.yahoo.comCorvus Pharmaceuticals reports Q4 EPS (18c), consensus (12c)March 26, 2025 | markets.businessinsider.comEntryPoint Capital LLC Purchases New Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)EntryPoint Capital LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 116,645 shares of the company's stock,March 26, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | seekingalpha.comCorvus Pharmaceuticals outlines clinical milestones for soquelitinib in 2025March 25, 2025 | msn.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | globenewswire.comCorvus shares progress on soquelitinib in T cell lymphoma trialMarch 22, 2025 | uk.investing.comCorvus announces presentation of data from Phase 1/1b trial of soquelitinibMarch 22, 2025 | markets.businessinsider.comCorvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell LymphomaMarch 20, 2025 | globenewswire.comCorvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 19, 2025 | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from AnalystsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has received a consensus recommendation of "Buy" from the five analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationMarch 18, 2025 | marketbeat.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025March 17, 2025 | globenewswire.comCorvus Pharmaceuticals announces initiation of Phase 2 trial of soquelitinibMarch 12, 2025 | markets.businessinsider.comCorvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)March 12, 2025 | globenewswire.comCorvus Pharmaceuticals (CRVS) to Release Earnings on TuesdayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comCorvus Pharmaceuticals: Small Market, Many Competitors, Low Cash BalanceMarch 3, 2025 | seekingalpha.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Buy" by AnalystsShares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Buy" by the five analysts that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has given a strongFebruary 21, 2025 | marketbeat.comCorvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from BrokeragesShares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned an average recommendation of "Buy" from the five research firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strongJanuary 27, 2025 | marketbeat.comCantor Fitzgerald Forecasts CRVS FY2025 EarningsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Corvus Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings ofJanuary 22, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday.January 14, 2025 | marketbeat.comCorvus announces data from cohort 2 of Phase 1 trial of SoquelitinibJanuary 14, 2025 | markets.businessinsider.comCorvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisJanuary 13, 2025 | globenewswire.comGeode Capital Management LLC Increases Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Geode Capital Management LLC boosted its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 22.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 563,009 sharJanuary 8, 2025 | marketbeat.comCorvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comWe're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash BurnJanuary 7, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for CRVS FY2024 Earnings?Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company wJanuary 6, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for CRVS Q4 Earnings?Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at HC Wainwright issued their Q4 2024 EPS estimates for Corvus Pharmaceuticals in a research report issued on Thursday, January 2nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of ($January 3, 2025 | marketbeat.comCorvus Pharmaceuticals initiated with a Buy at H.C. WainwrightJanuary 3, 2025 | markets.businessinsider.comCorvus wins new buy from H.C. Wainwright despite recent selloffJanuary 3, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Corvus Pharmaceuticals (CRVS) with Buy RecommendationJanuary 3, 2025 | msn.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Buy" from AnalystsShares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Buy" by the four analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a buy recommendation and one has given a strong buy recommenJanuary 2, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at HC WainwrightHC Wainwright initiated coverage on Corvus Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $11.00 price target on the stock.January 2, 2025 | marketbeat.comMizuho Securities Sticks to Their Buy Rating for Corvus Pharmaceuticals (CRVS)December 20, 2024 | markets.businessinsider.comCorvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade)December 19, 2024 | seekingalpha.comCorvus Pharmaceuticals announce interim data from Phase 1 trial of soquelitinibDecember 18, 2024 | markets.businessinsider.comCorvus falls after early-stage data for eczema therapyDecember 18, 2024 | msn.comCorvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor TargetingDecember 18, 2024 | seekingalpha.comCorvus Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw unusually large options trading on Wednesday. Investors acquired 5,716 put options on the stock. This is an increase of 264% compared to the typical daily volume of 1,570 put options.December 18, 2024 | marketbeat.com Remove Ads Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼1.220.78▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼22▲CRVS Articles Average Week Remove Ads Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcus Biosciences News Chimerix News Avid Bioservices News Spyre Therapeutics News Intellia Therapeutics News Zymeworks News Vir Biotechnology News Nurix Therapeutics News Anavex Life Sciences News Oculis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVS Stock Free CRVS Stock Alerts